ArticleCancer immunology, immunotherapy : CII2026
Heterogeneity and prognostic significance of mast cell subsets in the tumor microenvironment of prostate cancer.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundProstate cancer (PC) is one of the malignant tumors with high incidence and mortality worldwide in men. Immune cells in the tumor microenvironment (TME), particularly mast cells, play important roles in tumor progression and prognosis. However, the dual roles of mast cells in PC have not been fully elucidated.
methodsIn this study, single-cell RNA sequencing (scRNA-seq), bulk RNA sequencing, and bioinformatics analyses were performed to investigate the heterogeneity of mast cell subsets in the TME of PC and their association with prognosis. Single-cell data from 39 PC tumor samples were analyzed, and prognostic prediction was validated using datasets including HMU, TCGA, and MSKCC cohorts. Non-negative matrix factorization was applied to cluster mast cell subsets, followed by analyses of subset-specific gene markers, transcription factor activity, and biological pathways. Survival analysis and ROC curve evaluation were conducted to assess prognostic value.
resultsMast cells in the TME of PC were classified into two distinct subsets, each characterized by unique gene markers and functional pathways. Mast cell1 was highly associated with pro-tumorigenic pathways, whereas mast cell2 predominantly exhibited antitumor immune regulatory properties. High expression of mast cell1 signatures was correlated with poorer survival outcomes, while high expression of mast cell2 signatures was associated with better survival. Key marker genes such as BIRC3 and FOS were identified as potential prognostic factors, high BIRC3 expression was significantly associated with unfavorable prognosis, whereas high FOS expression correlated with favorable prognosis.
conclusionThis study revealed functional heterogeneity of mast cell subsets in the TME of PC and their distinct roles in tumor progression. The identification of subset-specific marker genes provides novel molecular targets for clinical diagnosis, prognostic prediction, and personalized therapy in PC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.